An official website of the United States government
We propose an innovative machine learning paradigm enabling precision medicine for prioritizing cognitive assessments according to their relevance to Alzheimer's disease at the individual patient level. The paradigm tailors the cognitive biomarker discovery and cognitive assessment selection process to the brain morphometric characteristics of each individual patient. We implement this paradigm using a newly developed learning-to-rank method PLTR. Our empirical study on the ADNI data yields promising results to identify and prioritize individual-specific cognitive biomarkers as well as cognitive assessment tasks based on the individual's structural MRI data. The resulting top ranked cognitive biomarkers and assessment tasks have the potential to aid personalized diagnosis and disease subtyping.
more »
« less
Task Balanced Multimodal Feature Selection to Predict the Progression of Alzheimer’s Disease
The social and financial costs associated with Alzheimer's disease (AD) result in significant burdens on our society. In order to understand the causes of this disease, public-private partnerships such as the Alzheimer's Disease Neuroimaging Initiative (ADNI) release data into the scientific community. These data are organized into various modalities (genetic, brain-imaging, cognitive scores, diagnoses, etc.) for analysis. Many statistical learning approaches used in medical image analysis do not explicitly take advantage of this multimodal data structure. In this work we propose a novel objective function and optimization algorithm that is designed to handle multimodal information for the prediction and analysis of AD. Our approach relies on robust matrix-factorization and row-wise sparsity provided by the ℓ2,1- norm in order to integrate multimodal data provided by the ADNI. These techniques are jointly optimized with a classification task to guide the feature selection in our proposed Task Balanced Multimodal Feature Selection method. Our results, when compared against some widely used machine learning algorithms, show improved balanced accuracies, precision, and Matthew's correlation coefficients for identifying cognitive decline. In addition to the improved prediction performance, our method is able to identify brain and genetic biomarkers that are of interest to the clinical research community. Our experiments validate existing brain biomarkers and single nucleotide polymorphisms located on chromosome 11 and detail novel polymorphisms on chromosome 10 that, to the best of the authors' knowledge, have not previously been reported. We anticipate that our method will be of interest to the greater research community and have released our method's code online.11Code is provided at: https://github.com/minds-mines/TBMFSjl
more »
« less
- PAR ID:
- 10219630
- Date Published:
- Journal Name:
- 2020 IEEE 20th International Conference on Bioinformatics and Bioengineering (BIBE)
- Volume:
- 1
- Page Range / eLocation ID:
- 196 to 203
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
-
Alzheimer’s disease (AD) is a degenerative brain disease that affects millions of people around the world. As populations in the United States and worldwide age, the prevalence of Alzheimer’s disease will only increase. In turn, the social and financial costs of AD will create a difficult environment for many families and caregivers across the globe.By combining genetic information, brain scans, and clinical data, gathered over time through the Alzheimer’s Disease Neuroimaging Initiative(ADNI), we propose a newJoint High-Order Multi-Modal Multi-Task Feature Learning method to predict the cognitive performance and diagnosis of patients with and without AD.more » « less
-
Background: Machine learning is a promising tool for biomarker-based diagnosis of Alzheimer’s disease (AD). Performing multimodal feature selection and studying the interaction between biological and clinical AD can help to improve the performance of the diagnosis models. Objective: This study aims to formulate a feature ranking metric based on the mutual information index to assess the relevance and redundancy of regional biomarkers and improve the AD classification accuracy. Methods: From the Alzheimer’s Disease Neuroimaging Initiative (ADNI), 722 participants with three modalities, including florbetapir-PET, flortaucipir-PET, and MRI, were studied. The multivariate mutual information metric was utilized to capture the redundancy and complementarity of the predictors and develop a feature ranking approach. This was followed by evaluating the capability of single-modal and multimodal biomarkers in predicting the cognitive stage. Results: Although amyloid-β deposition is an earlier event in the disease trajectory, tau PET with feature selection yielded a higher early-stage classification F1-score (65.4%) compared to amyloid-β PET (63.3%) and MRI (63.2%). The SVC multimodal scenario with feature selection improved the F1-score to 70.0% and 71.8% for the early and late-stage, respectively. When age and risk factors were included, the scores improved by 2 to 4%. The Amyloid-Tau-Neurodegeneration [AT(N)] framework helped to interpret the classification results for different biomarker categories. Conclusion: The results underscore the utility of a novel feature selection approach to reduce the dimensionality of multimodal datasets and enhance model performance. The AT(N) biomarker framework can help to explore the misclassified cases by revealing the relationship between neuropathological biomarkers and cognition.more » « less
-
null (Ed.)Alzheimer’s Disease (AD) is a chronic neurodegenerative disease that causes severe problems in patients’ thinking, memory, and behavior. An early diagnosis is crucial to prevent AD progression; to this end, many algorithmic approaches have recently been proposed to predict cognitive decline. However, these predictive models often fail to integrate heterogeneous genetic and neuroimaging biomarkers and struggle to handle missing data. In this work we propose a novel objective function and an associated optimization algorithm to identify cognitive decline related to AD. Our approach is designed to incorporate dynamic neuroimaging data by way of a participant-specific augmentation combined with multimodal data integration aligned via a regression task. Our approach, in order to incorporate additional side-information, utilizes structured regularization techniques popularized in recent AD literature. Armed with the fixed-length vector representation learned from the multimodal dynamic and static modalities, conventional machine learning methods can be used to predict the clinical outcomes associated with AD. Our experimental results show that the proposed augmentation model improves the prediction performance on cognitive assessment scores for a collection of popular machine learning algorithms. The results of our approach are interpreted to validate existing genetic and neuroimaging biomarkers that have been shown to be predictive of cognitive decline.more » « less
-
Alzheimer's Disease (AD) is a chronic neurodegenerative disease that severely impacts patients' thinking, memory and behavior. To aid automatic AD diagnoses, many longitudinal learning models have been proposed to predict clinical outcomes and/or disease status, which, though, often fail to consider missing temporal phenotypic records of the patients that can convey valuable information of AD progressions. Another challenge in AD studies is how to integrate heterogeneous genotypic and phenotypic biomarkers to improve diagnosis prediction. To cope with these challenges, in this paper we propose a longitudinal multi-modal method to learn enriched genotypic and phenotypic biomarker representations in the format of fixed-length vectors that can simultaneously capture the baseline neuroimaging measurements of the entire dataset and progressive variations of the varied counts of follow-up measurements over time of every participant from different biomarker sources. The learned global and local projections are aligned by a soft constraint and the structured-sparsity norm is used to uncover the multi-modal structure of heterogeneous biomarker measurements. While the proposed objective is clearly motivated to characterize the progressive information of AD developments, it is a nonsmooth objective that is difficult to efficiently optimize in general. Thus, we derive an efficient iterative algorithm, whose convergence is rigorously guaranteed in mathematics. We have conducted extensive experiments on the Alzheimer's Disease Neuroimaging Initiative (ADNI) data using one genotypic and two phenotypic biomarkers. Empirical results have demonstrated that the learned enriched biomarker representations are more effective in predicting the outcomes of various cognitive assessments. Moreover, our model has successfully identified disease-relevant biomarkers supported by existing medical findings that additionally warrant the correctness of our method from the clinical perspective.more » « less
- Free Publicly Accessible Full Text
-
Accepted Manuscript1.0
- Conference Paper:
- https://doi.org/10.1109/BIBE50027.2020.00040
